WO1998048032A2 - POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE - Google Patents

POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE Download PDF

Info

Publication number
WO1998048032A2
WO1998048032A2 PCT/EP1998/001996 EP9801996W WO9848032A2 WO 1998048032 A2 WO1998048032 A2 WO 1998048032A2 EP 9801996 W EP9801996 W EP 9801996W WO 9848032 A2 WO9848032 A2 WO 9848032A2
Authority
WO
WIPO (PCT)
Prior art keywords
poly
asp
glu
acid
glutamic acid
Prior art date
Application number
PCT/EP1998/001996
Other languages
French (fr)
Other versions
WO1998048032A3 (en
Inventor
David A. Tirrell
Michael Del Grosso
Rainer Siegmeier
Andreas Bommarius
Original Assignee
Donlar Corporation
University Of Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Donlar Corporation, University Of Massachusetts filed Critical Donlar Corporation
Priority to EP98922651A priority Critical patent/EP0915987A2/en
Publication of WO1998048032A2 publication Critical patent/WO1998048032A2/en
Publication of WO1998048032A3 publication Critical patent/WO1998048032A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Definitions

  • the terms polymer and copolymer comprise 5 to approx 200 amino acid units.
  • the invention also refers to a method for producing said polymers and copolymers by means of a microbiological process.
  • a further object of the invention is directed to the use of said polymers and copolymers as sequestering and dispersing agent.
  • Polyaspartic acids produced chemically from L- or DL-aspartic acid or suitable precursors, their salts as well as copolymers with other copolymerizable compounds are used as water-soluble sequestering agent and dispersing agents .
  • Polyamino acids and their salts are accessible in various methods of chemical production. Different methods of production and a few properties of polyamino acids are described, e.g., in Nachr. Chem. Tech. Lab., 1996, 44, 1167 - 1170 as well as in Hydrophylic Polymers, Performance with Environmental Acceptance, editor: J. Edward Glass, ACE, Washington, 1996, Commercial Poly (Aspartic Acid) and It's Uses, K.C. Low, A. P. Wheeler, L.P. Koskan, 99-111.
  • sodium salts of polyaspartic acids are obtained via the thermal polymerization of aspartic acid:
  • maleic acid anhydride is converted via maleic acid into fumaric acid, which is aminated in a following chemical or enzymatic method step to the ammonium salt of aspartic acid.
  • the free aspartic acid isolated therefrom is subjected to a solid-phase polymerization to the primary polymerization product.
  • suitable catalysts such as phosphoric acid.
  • maleic acid anhydride or maleic acid anhydride derivatives such as maleic acid ammonium salts, maleic amide acid, maleic amide acid ammonium salts can be thermally polymerized to a primary polymerization product in the presence of nitrogen- containing compounds such as ammonia but also of ammonium salts such as ammonium carbonate.
  • the primarily formed polymerization products are distinguished by polysuccinimide structural elements which result in subsequent hydrolysis in polyaspartic acids with ⁇ - and ⁇ - linked aspartic acid units.
  • the ⁇ / ⁇ ratio can be determined via NMR spectroscopic methods.
  • An ⁇ / ⁇ ratio of approximately 30:70 which can be influenced only slightly, results for all polyaspartic acids obtained according to the thermal polymerization methods and alkaline hydrolysis described here.
  • the main production methods described up to the present determine the structural parameters such as, e.g., the molecular weight, the linearity and the properties correlating therewith as well as the action in various applications and the biological degradability.
  • the EP-patent application 256 423 of Chisso discloses a process for the manufacture of ⁇ -poly-L-lysine, derived from Streptomyces albulus subspecies lysinopolymerus No. 346-D.
  • the process for the manufacture of of ⁇ -poly-L- lysine is characterized by the addition of sugar to the culturing medium.
  • the EP-A 0 557 954 refers to a process for the manufacture of ⁇ -poly-L-lysine with immobilized bacterial cells under aerobic conditions.
  • An isolated ⁇ -polyglutamate hydrolase is known from the EP- A 559 175 and US 5,356,805. Takeda Chemical discloses in the EP-A 410 638 a process to the manufacture of polyglutamic acid.
  • the microorganisms used for the polymerisation of L-glutamic acid were bacteria such as Bacillus subtilis or Bacillus licheniformis .
  • the product contains poly- ⁇ -L-glutamic acid with a wide spectrum of Glu-units in the polymer.
  • Poly- ⁇ -L-Glu has not been synthesized either directly through microbiological methods.
  • chemically generated poly-Glu the same observations and arguments hold as for chemcally generated poly-Asp.
  • the polymerisation degree is well defined and only dependent on the length of the polynucleotide which is used in the microbiological manufacturing process .
  • the task to find the a. m. polymers consisting of poly- ⁇ -L- Asp, poly- ⁇ -L-glu or copolymers of both amino acids that feature improved properties with respect to biological degradability and discoloration is solved by employing a oligonucleotide construct that encodes the desired sequence of Asp polymers (or Asp/Glu polymers) .
  • the amino acid Glu is encoded by two codons , GAA and GAG. In certain organisms such as E. coli , Glu is preferably encoded by GAA. Asp is encoded by two codons as well, GAC and GAT. The latter is preferred in many organisms such as E. coli .
  • the oligonucleotide construct encoding for the desired Asp length (or Asp/Glu length) is cloned into a plasmid.
  • Cells of the desired host cell line such as Escherichia coli , Bacillus subtilis ox Corynebacterium glutamicum, are transformed with the altered plasmids, and the genetic information expressed.
  • the oligonucleotide duplex which encodes the desired Glu or Asp or Glu/Asp amino acid sequence of the predetermined number of amino acid units of each polymer chain is synthesized on a DNA synthesizer.
  • the oligonucleotides are purified by electrophoresis on a polyacrylamide denaturing gel, annealed, enzymatically phosphorylated at the 5' termini, and ligated with BamUI -digested, phosphatase- treated plasmid pUC18.
  • the sequence of the insert is verified by a technique such as the Sanger dideoxy sequencing strategy.
  • E. coli strains are transformed with the recombinant plasmid and marked by an appropriate technique such as insertional inactivation of a gene or resistance against antibiotics.
  • a Glu/Asp sequence which by itself is a multimer of a simpler Glu/Asp sequence the recombinant plasmid is digested and affords a DNA fragment encoding the desired poly-Glu/Asp sequence.
  • This DNA is purified on a polyacrylamide gel and self-ligated in head- to-tail fashion with T4 DNA ligase to yield a population of multimers. A portion of the ligation mixture is analyzed on a 1.5% agarose gel. The ligation mixture is cloned into a plasmid such as pUC803 or pUC18. E. coli cells are then transformed with the recombinant plasmids .
  • a plasmid containing the repeat units of the DNA monomer is isolated, and the nucleotide sequence confirmed by sequencing of the double-stranded DNA.
  • the BamRI segment is recovered, purified and inserted into a suitable expression vector.
  • the ligation mix is used to transform E. coli cells, and the presence and orientation of the insert are checked by digestion with restriction enzymes BamHI and Aval , respectively.
  • the fusion protein is purified by standard techniques such as affinity chromatography, precipitation in organic solvent, and the like. Electrophoretic purification on a non-denaturing polyacrylamide gel affords a product which migrates as a single band at the expected molecular weight and which yields amino acid analyses consistent with the desired sequence .
  • the new aminoacid polymers and copolymers have many fold usefulness in any kind of water treatment and relevant processes :
  • Polyaspartic acid Na-salts have a dispersing action which reinforces the primary washing power.
  • Polyaspartic acids and their salts are used in washing [detergent] - and cleaning agents.
  • the detergents can be powdery or also be present in liquid form.
  • the composition of the washing- and cleaning agent formulations can be very different. Washing- and cleaning agent formulations customarily contain 2 to 50 % by weight surfactants and optional builders. This data applies both to liquid and to powdery detergents. Washing- and cleaning agent formulations customary in Europe, the USA and Japan are to be found, e.g., in Chemical and Engn. News, vol. 67, 35 (1989) in table form.
  • washing- and cleaning agents can be gathered from Ullmanns Encyklopadie der ischen Chemie, Verlag Chemie, Weinheim, 1983, 4 edition, pp. 63 - 160.
  • the use of polyaspartic acid in washing- and cleaning agents is described, among other places, in WO 95/16020, WO 95/16726, DE 44 30 520, DE 44 28 638, DE 44 28 597.
  • Inhibitors are used in cooling-water circuits, in the treating of boiler and feed water and in the desalination of see water for avoiding and eliminating precipates and coatings .
  • Polyaspartic acids prevent and/or delay the crystallization of alkaline-earth salts such as calcium carbonate, calcium sulfate, etc. The action thereby is far below the concentrations necessary for complex formation (threshold effect) .
  • Polyaspartic acid synthezised by thermal condensation of L-aspartic acid, is described as an inhibitor of corrosion in Little et al .
  • thermal Polyaspartate surface reactive peptides and polymers, pp. 263-279, ACS Symposium Series 444 (1990) .
  • Thermal polyaspartate binds to surfaces of mild steel and moderately supresses both anodic and cathodic corrosion reactions .
  • the see water contains sulfate.
  • the petroleum is accompanied by formation water containing barium ions and strontium ions. If the formation water and the see water mix, poorly soluble Ba sulfates and Sr sulfates form which may possibly clog boreholes and pipelines. Polyaspartic acids prevent and/or delay the crystallization of the precipitates so that the undesired coating formations do not occur.
  • Natural gas standing under pressure has a residual moisture content in the winning process. Salts are dissolved in this residual moisture. During the winning [extraction] process, especially during the expansion of the gas, a critical pressure is dropped below which results in a crystallizing out of the salts and a clogging of the porous sandstone .
  • Polyaspartic acids prevent and/or delay the crystallization of the salts in both instances on account of their dispersing properties.
  • Amino acid analyses were carried out on an apparatus like, for example, the Applied Biosystems 420/130A derivatizer/analyzer device.
  • Oligonucleotides were prepared by means of ⁇ - cyanoethylphosphorus amidite chemistry on a synthesizer like Biosearch Model 8700 and purified by means of 10 % denaturing polyacrylamid gel electrophoresis .
  • the purified oligonucleotides were annealed at 80 °C and allowed to cool off for several hours until room temperature.
  • the double strand was phosphorylated by T4-polynucleotide kinase, precipitated in ethanol and dried in a vacuum.
  • the double strand was ligated into a plasmid like pUC18 which had been cleaved by restriction endonucleases like, e.g., Eco RT or Bam HI and transformed in cells like, e.g., E. coli DH5 ⁇ F' .
  • restriction endonucleases like, e.g., Eco RT or Bam HI
  • cells like, e.g., E. coli DH5 ⁇ F' .
  • the cells were cultivated at 37 °C on a medium like 2xYT under the addition of ampicillin (about 0.2 mg/ml) , isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) (0.025 mg/ml) and a chromogenic substrate like 5-bromo-4- chloro-3-indolyl- ⁇ -D-galactopyranoside (called X-Gal here) which turned blue in the case of cells with active ⁇ - galactosidase gene but remained white in the case of cells which had lost the corresponding activity by inserting inactivation of the ⁇ -galactosidase gene.
  • ampicillin about 0.2 mg/ml
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • X-Gal 5-bromo-4- chloro-3-indolyl- ⁇ -D-galactopyranoside
  • Plasmid DNA from the white transformants is sequenced in order to verify the identity of the inserted DNA, e.g. by sequenase 2.0 of Amersham Life Sciences. After isolation of the recombinant plasmid from the 2xYT culture medium the DNA was digested by the restriction endonuclease BanI and the fragments separated by non-denaturing PAGE and the interesting DNA monomer washed down.
  • the purified DNA monomer is self- ligated with T4 DNA ligase in order to produce a distribution of multimers.
  • the multimers are separated by electrophoresis and ligated into a dephosphorylated, high copy number cloning vector digested with BanI.
  • the recombinant plasmid was transformed into a strain like E. coli. Transformants are analyzed by analysis of the restriction enzyme digestion pattern and the desired DNA chain length (with the desired number of repeating units) selected. Construction of the bacterial expression vector
  • the recombinant plasmids from the transformants were digested with restriction endonucleases like BamHI , the multimer fragments separated on 1 % agarose gel electrophoresis and recovered by extraction e.g. in phenol, phenol/chloroform or ethanol. Transformants were checked by digestion with nucleases like Aval for the presence and orientation of multimers. Transformants with correct sequence were used for the transformation of the expression host.
  • the fusion protein was obtained by centrifugation after the thawed [defrosted] cells had been treated successively twice with EDTA/surfactant , then with lipase, finally with organic solvents (chloroform/methanol) and were finally washed with water.
  • An affinity chromatography then selectively follows, e.g., via glutathione-linked sepharose . Cleaving of the fusion protein
  • the fusion protein is preferably cleaved by the bromocyanogen method (cf . B.J. Smith, Methods in Biology, New Protein Techniques, Humana, Clifton, NH, 1988) . After the cleaving the solvent is drawn off by vacuum evaporation and the insoluble portion recovered by centrifugation and dried by lyophilization.

Abstract

The invention provides Poly-(α-L-aspartic acid) (= poly-L-α-Asp), Poly-(α-L-glutamic acid) and new copolymers of L-Asp and L-Glu with essentially α-linkages as well as salts of said polymers and copolymers. A method for producing said polyamino acids comprises employing an oligonucleotide construct encoding the sequence of the desired polymer, cloning the oligonucleotide into a plasmid, transformation of host cells with the plasmid and expression of the genetic information. Because of their good biological degradability the new poly-L-α-amino acids can be used as co-builders, sequestering agents and corrosion inhibitors.

Description

Poly- (α-L-aspartic acid) , Poly- (α-L-glutamic acid) and copolymers of L-Asp and L-Glu, method for their production and their use
Introduction and background
The invention refers to Poly- (α-L-aspartic acid) (= poly- α-Asp) , Poly- (α-L-glutamic acid) and new copolymers of L-Asp and L-Glu with essentially α-linkages as well as salts of said polymers and copolymers. The terms polymer and copolymer comprise 5 to approx 200 amino acid units. The invention also refers to a method for producing said polymers and copolymers by means of a microbiological process. A further object of the invention is directed to the use of said polymers and copolymers as sequestering and dispersing agent.
Polyaspartic acids (poly-asp) produced chemically from L- or DL-aspartic acid or suitable precursors, their salts as well as copolymers with other copolymerizable compounds are used as water-soluble sequestering agent and dispersing agents .
Disadvantages of the poly-aspartic acids and salts as well as relevant copolymers currently used are their incomplete biodegradability as well as their discoloration to a dark product stemming from the harsh conditions of their manufacture. For use in the laundry detergent industry the dark discoloration is a major disadvantage. The task addressed by this application is to provide new polymers of amino acids which feature improved biodegradability together with improved or at least not worsened abilities for complexation of divalent metal ions such as calcium or magnesium. Furthermore, there is demand for polymers which are colorless or nearly colorless in solid condition or in aqueous solution.
Polyamino acids and their salts are accessible in various methods of chemical production. Different methods of production and a few properties of polyamino acids are described, e.g., in Nachr. Chem. Tech. Lab., 1996, 44, 1167 - 1170 as well as in Hydrophylic Polymers, Performance with Environmental Acceptance, editor: J. Edward Glass, ACE, Washington, 1996, Commercial Poly (Aspartic Acid) and It's Uses, K.C. Low, A. P. Wheeler, L.P. Koskan, 99-111.
According to the above, sodium salts of polyaspartic acids are obtained via the thermal polymerization of aspartic acid: To this end maleic acid anhydride is converted via maleic acid into fumaric acid, which is aminated in a following chemical or enzymatic method step to the ammonium salt of aspartic acid. The free aspartic acid isolated therefrom is subjected to a solid-phase polymerization to the primary polymerization product. In a modified method the course of the reaction as well as the product properties can be influenced by the addition of suitable catalysts such as phosphoric acid. Alternatively, maleic acid anhydride or maleic acid anhydride derivatives such as maleic acid ammonium salts, maleic amide acid, maleic amide acid ammonium salts can be thermally polymerized to a primary polymerization product in the presence of nitrogen- containing compounds such as ammonia but also of ammonium salts such as ammonium carbonate. The primarily formed polymerization products are distinguished by polysuccinimide structural elements which result in subsequent hydrolysis in polyaspartic acids with α- and β- linked aspartic acid units. The α/β ratio can be determined via NMR spectroscopic methods. An α/β ratio of approximately 30:70, which can be influenced only slightly, results for all polyaspartic acids obtained according to the thermal polymerization methods and alkaline hydrolysis described here.
The main production methods described up to the present determine the structural parameters such as, e.g., the molecular weight, the linearity and the properties correlating therewith as well as the action in various applications and the biological degradability.
Besides the a. m. chemical processes there exist only a few biological routes to amino acid polymers:
The EP-patent application 256 423 of Chisso discloses a process for the manufacture of ε-poly-L-lysine, derived from Streptomyces albulus subspecies lysinopolymerus No. 346-D. The process for the manufacture of of ε-poly-L- lysine is characterized by the addition of sugar to the culturing medium. The EP-A 0 557 954 refers to a process for the manufacture of ε-poly-L-lysine with immobilized bacterial cells under aerobic conditions.
An isolated γ-polyglutamate hydrolase is known from the EP- A 559 175 and US 5,356,805. Takeda Chemical discloses in the EP-A 410 638 a process to the manufacture of polyglutamic acid. The microorganisms used for the polymerisation of L-glutamic acid were bacteria such as Bacillus subtilis or Bacillus licheniformis . The product contains poly-α-L-glutamic acid with a wide spectrum of Glu-units in the polymer.
The State of the Art concerning biological routes to other poly-amino acids is very limited: Tirrell et al . have done some work - see „Biomolecular Materials", Special Report, Chemical & Engineering News, Dec. 19, 1994, p. 40-51 and „Synthesis of biopolymers : proteins, polyesters, polysaccharides and polynucleotides", Current Opinions in Solid State & Materials Science 1996, Vol. 1, p. 407-411.
Poly-L-Asp of the desired length and purity has not been synthesized before through biological methods. The closest example in the literature (G. Zhang, M.J. Fournier, T.L.
Mason and D.A. Tirrell, Macromolecules 1992, 25, 3601-3603) is a 76-mer with the structure Asp-Glu- (Glu17-Asp) 4-OH.
Poly-α-L-Glu has not been synthesized either directly through microbiological methods. For chemically generated poly-Glu the same observations and arguments hold as for chemcally generated poly-Asp.
Summary of the invention
We have found Poly- (α-L-aspartic acid) (= Poly (α-L-Asp) m) and Poly- (α-L-glutamic acid) (= Poly (α-L-Glu) m) with a polymerisation degree m selected within 5 to 200. The polymerisation degree is well defined and only dependent on the length of the polynucleotide which is used in the microbiological manufacturing process . We further have found copolymers on the basis of L-Asp and L-Glu with essentially only α-linkages and well defined position of the L-amino acids over the length of the copolymer, the polymerisation degree (= number of amino acid units) of which is selected of 5 to 200.
The task to find the a. m. polymers consisting of poly-α-L- Asp, poly-α-L-glu or copolymers of both amino acids that feature improved properties with respect to biological degradability and discoloration is solved by employing a oligonucleotide construct that encodes the desired sequence of Asp polymers (or Asp/Glu polymers) . The amino acid Glu is encoded by two codons , GAA and GAG. In certain organisms such as E. coli , Glu is preferably encoded by GAA. Asp is encoded by two codons as well, GAC and GAT. The latter is preferred in many organisms such as E. coli . The oligonucleotide construct encoding for the desired Asp length (or Asp/Glu length) is cloned into a plasmid. Cells of the desired host cell line, such as Escherichia coli , Bacillus subtilis ox Corynebacterium glutamicum, are transformed with the altered plasmids, and the genetic information expressed. Detailed description of the invention
The procedure to obtain the poly-amino acids follows that described in the' publication of G. Zhang, M.J. Fournier, T.L. Mason and D.A. Tirrell, Macromolecules 1992, 25, 3601- 3603, and is described below.
Fermentations in complex media, DNA treatments and transformations are conducted as described in Sambrook, Frisch and Maniatis (J. Sambrook et al . , Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Press, 1989) .
The oligonucleotide duplex which encodes the desired Glu or Asp or Glu/Asp amino acid sequence of the predetermined number of amino acid units of each polymer chain is synthesized on a DNA synthesizer. The oligonucleotides are purified by electrophoresis on a polyacrylamide denaturing gel, annealed, enzymatically phosphorylated at the 5' termini, and ligated with BamUI -digested, phosphatase- treated plasmid pUC18. The sequence of the insert is verified by a technique such as the Sanger dideoxy sequencing strategy. E. coli strains are transformed with the recombinant plasmid and marked by an appropriate technique such as insertional inactivation of a gene or resistance against antibiotics.
Should a Glu/Asp sequence be desired which by itself is a multimer of a simpler Glu/Asp sequence the recombinant plasmid is digested and affords a DNA fragment encoding the desired poly-Glu/Asp sequence. This DNA „monomer" is purified on a polyacrylamide gel and self-ligated in head- to-tail fashion with T4 DNA ligase to yield a population of multimers. A portion of the ligation mixture is analyzed on a 1.5% agarose gel. The ligation mixture is cloned into a plasmid such as pUC803 or pUC18. E. coli cells are then transformed with the recombinant plasmids . A plasmid containing the repeat units of the DNA monomer is isolated, and the nucleotide sequence confirmed by sequencing of the double-stranded DNA. The BamRI segment is recovered, purified and inserted into a suitable expression vector. The ligation mix is used to transform E. coli cells, and the presence and orientation of the insert are checked by digestion with restriction enzymes BamHI and Aval , respectively.
Individual colonies of the expression host, which contained recombinant plasmid of the correct sequence and orientation, either as monomer or in repeating units, were used to inoculate a preculture of LB medium with an antibiotic. After growth the culture was used for inoculation of the main culture (also containing antibiotics) in fermentation media such as, e.g., LB or 2xYT. Protein expression was achieved by the addition of an inductor (IPTG = isopropylthiogalactopyranoside) toward the end of the logarithmic growth phase. The rate of cell growth is normal prior to induction but declines as protein product appears in whole cell lysates analyzed on a 12% SDS-polyacrylamide gel. As a control, no such product was found in crude lysates of cells lacking the artificial coding sequence. The cells were harvested two hours later by centrifugation.
After cell lysis, e.g. in a homogenizer, the fusion protein is purified by standard techniques such as affinity chromatography, precipitation in organic solvent, and the like. Electrophoretic purification on a non-denaturing polyacrylamide gel affords a product which migrates as a single band at the expected molecular weight and which yields amino acid analyses consistent with the desired sequence .
The new aminoacid polymers and copolymers have many fold usefulness in any kind of water treatment and relevant processes :
• Use as co-builder in detergents:
In the formulation of modern universal detergents co- builders are considerably significant for supporting the actual builders [skeletal substances] . Their task is to eliminate the calcium- and magnesium ions stemming in part from the contamination and in part from the water and to force the surfactant action therewith.
Polyaspartic acid Na-salts have a dispersing action which reinforces the primary washing power. Polyaspartic acids and their salts are used in washing [detergent] - and cleaning agents. The detergents can be powdery or also be present in liquid form. The composition of the washing- and cleaning agent formulations can be very different. Washing- and cleaning agent formulations customarily contain 2 to 50 % by weight surfactants and optional builders. This data applies both to liquid and to powdery detergents. Washing- and cleaning agent formulations customary in Europe, the USA and Japan are to be found, e.g., in Chemical and Engn. News, vol. 67, 35 (1989) in table form. Further data about the composition of washing- and cleaning agents can be gathered from Ullmanns Encyklopadie der technischen Chemie, Verlag Chemie, Weinheim, 1983, 4 edition, pp. 63 - 160. The use of polyaspartic acid in washing- and cleaning agents is described, among other places, in WO 95/16020, WO 95/16726, DE 44 30 520, DE 44 28 638, DE 44 28 597.
• Use in water treatment :
Inhibitors are used in cooling-water circuits, in the treating of boiler and feed water and in the desalination of see water for avoiding and eliminating precipates and coatings . Polyaspartic acids prevent and/or delay the crystallization of alkaline-earth salts such as calcium carbonate, calcium sulfate, etc. The action thereby is far below the concentrations necessary for complex formation (threshold effect) .
• Use as corrosion inhibitor:
Polyaspartic acid, synthezised by thermal condensation of L-aspartic acid, is described as an inhibitor of corrosion in Little et al . „Corrosion Inhibi tion by thermal Polyaspartate", surface reactive peptides and polymers, pp. 263-279, ACS Symposium Series 444 (1990) . Thermal polyaspartate binds to surfaces of mild steel and moderately supresses both anodic and cathodic corrosion reactions .
• Use in petroleum production [from wells]
In the production of petroleum, especially in the North See, the oil is won with the aid of see water. The see water contains sulfate. The petroleum is accompanied by formation water containing barium ions and strontium ions. If the formation water and the see water mix, poorly soluble Ba sulfates and Sr sulfates form which may possibly clog boreholes and pipelines. Polyaspartic acids prevent and/or delay the crystallization of the precipitates so that the undesired coating formations do not occur.
• Use for desalination in natural gas production:
In the winning of natural gas relatively dry natural gas flows through saturated salt brines and absorbs moisture. This produces a concentration and possibly a supersaturation of the salt brine, which crystallizes salts out, especially NaCl and KC1. The crystallizates clog the porous sandstone, which lets the natural gas through only very poorly or not at all any more.
Natural gas standing under pressure has a residual moisture content in the winning process. Salts are dissolved in this residual moisture. During the winning [extraction] process, especially during the expansion of the gas, a critical pressure is dropped below which results in a crystallizing out of the salts and a clogging of the porous sandstone .
Polyaspartic acids prevent and/or delay the crystallization of the salts in both instances on account of their dispersing properties.
Examples and reference examples
Reference example 1 : Polyaspartate starting with L- aspartic acid
133 g L-aspartic acid were placed in a 1 1 round-bottomed flask and heated in a rotary evaporator at a pressure of 20-100 mbar to 230-250 °C for 4 h. The powdery polysuccinimide produced was dissolved in sodium hydroxide solution (50 % by weight) under agitation at 30-50 °C and the solution adjusted to pH 9-11. After the water was distilled of in the rotary evaporator under reduced pressure polyaspartic acid Na salt was obtained as solid.
Reference example 2 : Polyasparate [sic - aspartate? Here and below.] starting from rac-aspartic acid
Production analogous to the method starting from L-aspartic acid (see section 4.1)
Reference example 3 : Polyasparate starting from maleic acid anhydride and ammonia solution
Maleic acid anhydride was added to a solution of concentrated NH3 solution in a round-bottomed flask and the reaction mixture concentrated by evaporation in a rotary evaporator to dryness and the residue heated at 230-250 °C in the rotary evaporator for 4 h. The powdery polysuccinimide produced was dissolved in sodium hydroxide solution (50 % by weight) under agitation at 30-50 °C and the solution adjusted to pH 9-11. After the water was distilled of in the rotary evaporator under reduced pressure polyaspartic acid Na salt was obtained as solid.
Reference example 4 : Polyasparate starting from monoammonium maleate
Maleic acid anhydride was charged into a cone, ammonia solution in a round-bottomed flask. A monoammonium maleate slurry was obtained thereby. The precipitate was filtered off and pre-dried. The solid monoammonium maleate was now polymerized analogously to section 4.1.
Example 1 Poly- (α-L-asp) 48
Concerning the principles of the production of poly-α-L amino acids the following literature is referred to: Zhang et al . , Macromolecules 1992, 25, pp. 3601-3603 and Panitch et al . , Macromolecules 1997, pp. 42-49.
General remarks :
Fermentation in full medium, DNA treatments and transformations were carried out as described in Sambrook,
Frisch and Maniatis (J. Sambrook et al . , Molecular Cloning.
A Laboratory Manual, Cold Spring Harbor Press, 1989) .
Amino acid analyses were carried out on an apparatus like, for example, the Applied Biosystems 420/130A derivatizer/analyzer device.
Preparation of the synthetic DNA
Oligonucleotides were prepared by means of β- cyanoethylphosphorus amidite chemistry on a synthesizer like Biosearch Model 8700 and purified by means of 10 % denaturing polyacrylamid gel electrophoresis . The purified oligonucleotides were annealed at 80 °C and allowed to cool off for several hours until room temperature. The double strand was phosphorylated by T4-polynucleotide kinase, precipitated in ethanol and dried in a vacuum.
Cloning and amplification:
The double strand was ligated into a plasmid like pUC18 which had been cleaved by restriction endonucleases like, e.g., Eco RT or Bam HI and transformed in cells like, e.g., E. coli DH5αF' . The cells were cultivated at 37 °C on a medium like 2xYT under the addition of ampicillin (about 0.2 mg/ml) , isopropyl-β-D-thiogalactopyranoside (IPTG) (0.025 mg/ml) and a chromogenic substrate like 5-bromo-4- chloro-3-indolyl-β-D-galactopyranoside (called X-Gal here) which turned blue in the case of cells with active β- galactosidase gene but remained white in the case of cells which had lost the corresponding activity by inserting inactivation of the β-galactosidase gene.
Plasmid DNA from the white transformants is sequenced in order to verify the identity of the inserted DNA, e.g. by sequenase 2.0 of Amersham Life Sciences. After isolation of the recombinant plasmid from the 2xYT culture medium the DNA was digested by the restriction endonuclease BanI and the fragments separated by non-denaturing PAGE and the interesting DNA monomer washed down.
Polymerization of the DNA monomer and cloning of the multimer
In the case of Asp/Glu sequences representing multimers of a shorter Asp/Glu monomer the purified DNA monomer is self- ligated with T4 DNA ligase in order to produce a distribution of multimers. The multimers are separated by electrophoresis and ligated into a dephosphorylated, high copy number cloning vector digested with BanI. The recombinant plasmid was transformed into a strain like E. coli. Transformants are analyzed by analysis of the restriction enzyme digestion pattern and the desired DNA chain length (with the desired number of repeating units) selected. Construction of the bacterial expression vector
The recombinant plasmids from the transformants were digested with restriction endonucleases like BamHI , the multimer fragments separated on 1 % agarose gel electrophoresis and recovered by extraction e.g. in phenol, phenol/chloroform or ethanol. Transformants were checked by digestion with nucleases like Aval for the presence and orientation of multimers. Transformants with correct sequence were used for the transformation of the expression host.
Fermentation and protein expression
In both the cases of monomeric or multimeric Asp/Glu sequence, fermentation is conducted by vigorous aeration in a YT medium to an optical density of OD600 = 1.0, synthesis of the fusion protein is induced by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) at 0.4 mM. Cells are harvested 2 h after induction, e.g. by centrifugation at 4000 g for 20 min at 4°C. The pellet from the centrifugation is re-suspended in water and stored at -20 °C.
Protein purification
The fusion protein was obtained by centrifugation after the thawed [defrosted] cells had been treated successively twice with EDTA/surfactant , then with lipase, finally with organic solvents (chloroform/methanol) and were finally washed with water. An affinity chromatography then selectively follows, e.g., via glutathione-linked sepharose . Cleaving of the fusion protein
The fusion protein is preferably cleaved by the bromocyanogen method (cf . B.J. Smith, Methods in Biology, New Protein Techniques, Humana, Clifton, NH, 1988) . After the cleaving the solvent is drawn off by vacuum evaporation and the insoluble portion recovered by centrifugation and dried by lyophilization.
Example 2
Biological degradability of synthetically and fermentatively produced polyaspartates
In the determination of the aerobic biological degradability of organic substances in aqueous medium according to DIN EN 29888 (Zahn-Wellens method) a defined substance concentration with microorganisms (activated sludge) from a municipal sewage treatment plant is inoculated and subsequently aerated. The incubation takes place at room temperature in the dark. During the test time the decrease of substance concentration is followed via summation parameters like COD (chemical oxygen demand) and/or TOC (total organic carbon) . The degradability is defined as the decrease in COD or in TOC (expressed in per cent) during the test period, corrected by the particular blank value and relative to the initial concentration used.
Biological degradability according to Zahn-Wellens determined as CSB elimination after 28 days. Clarification sludge from the Hanau sewage treatment plant . Starting from L-aspartic acid from reference example 1 85
Starting from rac-aspartic acid from reference example 2 40
Starting from maleic acid anhydride/NH3 from reference example 3 30
Starting from monoammonium maleate from reference example 4 45
Starting from fermentative poly- (α-L-Asp) 48 from example 1 95 - 100 %

Claims

Claims
1. Poly- (╬▒-L-amino acids) selected from the Group Poly(╬▒- L-aspartic acid) m , Poly (╬▒-L-glutamic acid)n and
Poly (╬▒-L-Aspartic/glutamic acid)m, wherein m is a whole number selected from 5 to 200.
2. Process for the manufacture of Poly-╬▒-L-amino acids selected from the Group Poly (╬▒-L-aspartic acid)m , Pol (╬▒-L-glutamic acid)n and Poly (╬▒-L-Aspartic/glutamic acid)m, wherein m is a whole number selected from 5 to 200 comprising the steps a) the synthesis an oligonucleotide of lenght 3 x m, wherein m is the number of Asp or Glu or the sum of Asp and Glu-moieties coding for Asp and/or Glu b) the incorporation of the oligonucleotide into a plasmid together with a promoter c) the expression of the gene in a microorganism selected from the Group of E. coli, Corynebacterium glutamicum, Aspergillus niger, Bacillus subtilis d) the fermentation of the respective organism e) the isolation of the oligo-L-Asp (or oligo- (L- Asp) m- (L-Gllu) n) product .
3. Process as in claim 2, wherein the polymerisation degree m is precisely controlled by the length (1) of the oligonucleotide (m = 3 1) .
4. Process as in claim 2 or 3 , wherein m is selected from whole numbers between 10 and 150.
5. Use of Poly- (╬▒-L-amino acid) according to claim 1 as Co-builder in detergent-bleaching and cleaning- compositions .
6. Use of Poly- (╬▒-L-amino acids) according to claim 1 as sequestering agent in the water treatment .
7. Use of Poly- (╬▒-L-amino acids) according to claim 1 as corrosion inhibitor to suppress anodic and cathodic corrosion reactions.
PCT/EP1998/001996 1997-04-21 1998-04-06 POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE WO1998048032A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP98922651A EP0915987A2 (en) 1997-04-21 1998-04-06 POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4472797P 1997-04-21 1997-04-21
US60/044,727 1997-04-21

Publications (2)

Publication Number Publication Date
WO1998048032A2 true WO1998048032A2 (en) 1998-10-29
WO1998048032A3 WO1998048032A3 (en) 1999-01-28

Family

ID=21933997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001996 WO1998048032A2 (en) 1997-04-21 1998-04-06 POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE

Country Status (2)

Country Link
EP (1) EP0915987A2 (en)
WO (1) WO1998048032A2 (en)

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075548A2 (en) 2008-12-23 2010-07-01 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
EP2325206A2 (en) 2004-11-12 2011-05-25 Xencor, Inc. FC variants with altered binding to FCRN
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
EP2444423A1 (en) 2007-10-31 2012-04-25 Xencor Inc. Fc variants with altered binding to FcRn
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
WO2013192131A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2014078866A2 (en) 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
WO2014145806A2 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
WO2014177460A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
EP2808343A1 (en) 2007-12-26 2014-12-03 Xencor Inc. Fc variants with altered binding to FcRn
WO2015095684A1 (en) 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015149077A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016182751A1 (en) 2015-05-08 2016-11-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016207304A2 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
WO2017072210A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
WO2017191101A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
WO2017210443A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
WO2018033798A1 (en) 2016-08-17 2018-02-22 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018071919A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2018129522A1 (en) 2017-01-09 2018-07-12 Torch Therapeutics Conditionally effective bispecific therapeutics
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
WO2018220446A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
WO2018223002A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
EP3421495A2 (en) 2013-03-15 2019-01-02 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2019157340A1 (en) 2018-02-08 2019-08-15 Amgen Inc. Low ph pharmaceutical antibody formulation
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
WO2019204592A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019210147A1 (en) 2018-04-27 2019-10-31 Xencor, Inc. Dosing of a bispecific antibody that bind cd123 and cd3
WO2019232484A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
WO2019232528A1 (en) 2018-06-01 2019-12-05 Xencor, Inc. Dosing of a bispecific antibody that bind cd123 and cd3
WO2020010079A2 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
WO2020018556A1 (en) 2018-07-16 2020-01-23 Amgen Inc. Method of treating multiple myeloma
EP3611188A1 (en) 2014-11-06 2020-02-19 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding and methods of use
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
WO2020077276A2 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
WO2020154540A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
US10793621B2 (en) 2011-02-28 2020-10-06 Hoffmann-La Roche Inc. Nucleic acid encoding dual Fc antigen binding proteins
WO2021072298A1 (en) 2019-10-11 2021-04-15 Genentech, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
WO2021155042A1 (en) 2020-01-28 2021-08-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
EP3878866A1 (en) 2013-04-29 2021-09-15 F. Hoffmann-La Roche AG Fc-receptor binding modified asymmetric antibodies and methods of use
EP3928788A1 (en) 2014-11-26 2021-12-29 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
WO2022127793A1 (en) 2020-12-18 2022-06-23 珠海泰诺麦博生物技术有限公司 Respiratory syncytial virus-specific binding molecule
WO2022140701A1 (en) 2020-12-24 2022-06-30 Xencor, Inc. Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains
WO2023010031A1 (en) 2021-07-28 2023-02-02 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023015198A1 (en) 2021-08-04 2023-02-09 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2023175498A1 (en) 2022-03-17 2023-09-21 Pfizer Inc. Improved igg-degrading enzymes and methods of use thereof
WO2023196905A1 (en) 2022-04-07 2023-10-12 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2068971A (en) * 1980-01-30 1981-08-19 Searle & Co Recombinant DNA techniques
EP0410638A2 (en) * 1989-07-26 1991-01-30 Takeda Chemical Industries, Ltd. Method for producing polyglutamic acid or a salt thereof
EP0578451A2 (en) * 1992-07-10 1994-01-12 Rohm And Haas Company Polysuccinimide polymers and process for preparing polysuccinimide polymers
WO1995008996A1 (en) * 1993-09-30 1995-04-06 Gleich Gerald J Method for treatment of eosinophil-associated conditions
WO1995016020A1 (en) * 1993-12-11 1995-06-15 Basf Aktiengesellschaft Use of polyasparaginic acid in washing and cleaning agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2068971A (en) * 1980-01-30 1981-08-19 Searle & Co Recombinant DNA techniques
EP0410638A2 (en) * 1989-07-26 1991-01-30 Takeda Chemical Industries, Ltd. Method for producing polyglutamic acid or a salt thereof
EP0578451A2 (en) * 1992-07-10 1994-01-12 Rohm And Haas Company Polysuccinimide polymers and process for preparing polysuccinimide polymers
WO1995008996A1 (en) * 1993-09-30 1995-04-06 Gleich Gerald J Method for treatment of eosinophil-associated conditions
WO1995016020A1 (en) * 1993-12-11 1995-06-15 Basf Aktiengesellschaft Use of polyasparaginic acid in washing and cleaning agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. PANITCH ET AL.: "Poly(L-alanylglycine): Multigram-scale biosynthesis, crystallization, and structural analysis of chain-folded lamellae" MACROMOLECULES, vol. 30, no. 1, 13 January 1997, AM. CHEM. SOC., US, pages 42-49, XP002076902 cited in the application *
B.J. LITTLE AND C.S. SIKES: "Corrosion inhibition by thermal polyaspartate" ACS SYMPOSIUM SERIES 444, SURFACE REACTIVE PEPTIDES AND POLYMERS, 1991, AM. CHEM. SOC., WASHINGTON, DC, US, pages 263-279, XP002077101 cited in the application *
G. ZHANG ET AL.: "Biological synthesis of monodisperse derivatives of poly(alpha-L-glutamic acid): Model rodlike molecules" MACROMOLECULES, vol. 25, no. 13, 22 June 1992, AMCERICAN CHEM. SOC., US, pages 3601-3603, XP002076903 cited in the application *
J.G. TIRRELL ET AL.: "Biomolecular materials" CHEMICAL & ENGINEERING NEWS, 19 December 1994, WASHINGTON, US, pages 40-51, XP002076901 cited in the application *
M. SCHWAMBORN: "Polyasparagins{uren" NACHR. CHEM. TECH. LAB., vol. 44, no. 12, December 1996, VCH VERLAGSGESELLSCHAFT, WEINHEIM, FRG, pages 1167-1170, XP002076900 cited in the application *
See also references of EP0915987A2 *

Cited By (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325206A2 (en) 2004-11-12 2011-05-25 Xencor, Inc. FC variants with altered binding to FCRN
EP2325207A2 (en) 2004-11-12 2011-05-25 Xencor, Inc. FC variants with altered binding to FCRN
EP2332985A2 (en) 2004-11-12 2011-06-15 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
EP2444423A1 (en) 2007-10-31 2012-04-25 Xencor Inc. Fc variants with altered binding to FcRn
EP3138853A1 (en) 2007-10-31 2017-03-08 Xencor, Inc. Fc variants with altered binding to fcrn
EP2937361A2 (en) 2007-10-31 2015-10-28 Xencor Inc. Fc variants with altered binding to fcRn
EP4269443A2 (en) 2007-12-26 2023-11-01 Xencor, Inc. Fc variants with altered binding to fcrn
EP3825329A1 (en) 2007-12-26 2021-05-26 Xencor, Inc. Fc variants with altered binding to fcrn
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
EP3575317A1 (en) 2007-12-26 2019-12-04 Xencor, Inc. Fc variants with altered binding to fcrn
EP2808343A1 (en) 2007-12-26 2014-12-03 Xencor Inc. Fc variants with altered binding to FcRn
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
EP3318573A1 (en) 2008-12-23 2018-05-09 F. Hoffmann-La Roche AG Mmunoglobulin variants with altered binding to protein a
WO2010075548A2 (en) 2008-12-23 2010-07-01 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
US9890204B2 (en) 2009-04-07 2018-02-13 Hoffmann-La Roche Inc. Trivalent, bispecific antibodies
US10640555B2 (en) 2009-06-16 2020-05-05 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US11673945B2 (en) 2009-06-16 2023-06-13 Hoffmann-La Roche Inc. Bispecific antigen binding proteins
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US9994646B2 (en) 2009-09-16 2018-06-12 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
US10106600B2 (en) 2010-03-26 2018-10-23 Roche Glycart Ag Bispecific antibodies
US9879095B2 (en) 2010-08-24 2018-01-30 Hoffman-La Roche Inc. Bispecific antibodies comprising a disulfide stabilized-Fv fragment
US11618790B2 (en) 2010-12-23 2023-04-04 Hoffmann-La Roche Inc. Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10793621B2 (en) 2011-02-28 2020-10-06 Hoffmann-La Roche Inc. Nucleic acid encoding dual Fc antigen binding proteins
US10611825B2 (en) 2011-02-28 2020-04-07 Hoffmann La-Roche Inc. Monovalent antigen binding proteins
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
US9688758B2 (en) 2012-02-10 2017-06-27 Genentech, Inc. Single-chain antibodies and other heteromultimers
WO2013192131A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
US11421022B2 (en) 2012-06-27 2022-08-23 Hoffmann-La Roche Inc. Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US11407836B2 (en) 2012-06-27 2022-08-09 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US10106612B2 (en) 2012-06-27 2018-10-23 Hoffmann-La Roche Inc. Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
US9695233B2 (en) 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
US10683345B2 (en) 2012-07-13 2020-06-16 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
WO2014078866A2 (en) 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
EP3936521A1 (en) 2013-03-15 2022-01-12 Xencor, Inc. Heterodimeric proteins
EP3421495A2 (en) 2013-03-15 2019-01-02 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3587448A1 (en) 2013-03-15 2020-01-01 Xencor, Inc. Heterodimeric proteins
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
WO2014145806A2 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins
EP3628685A1 (en) 2013-04-29 2020-04-01 F. Hoffmann-La Roche AG Human fcrn-binding modified antibodies and methods of use
WO2014177460A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
EP3878866A1 (en) 2013-04-29 2021-09-15 F. Hoffmann-La Roche AG Fc-receptor binding modified asymmetric antibodies and methods of use
US10323099B2 (en) 2013-10-11 2019-06-18 Hoffmann-La Roche Inc. Multispecific domain exchanged common variable light chain antibodies
WO2015095684A1 (en) 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
EP3835318A1 (en) 2014-01-15 2021-06-16 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015107026A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
EP3699195A2 (en) 2014-03-28 2020-08-26 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
EP3954713A2 (en) 2014-03-28 2022-02-16 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2015149077A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
EP3842453A1 (en) 2014-11-06 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn- and protein a-binding properties
EP3611188A1 (en) 2014-11-06 2020-02-19 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding and methods of use
EP3928788A1 (en) 2014-11-26 2021-12-29 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
WO2016086186A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies including binding to cd8
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10633457B2 (en) 2014-12-03 2020-04-28 Hoffmann-La Roche Inc. Multispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2016182751A1 (en) 2015-05-08 2016-11-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
EP4059514A1 (en) 2015-05-08 2022-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10906971B2 (en) 2015-06-26 2021-02-02 Sanofi Biotechnology SAS Monoclonal anti-IL-1RAcP antibodies
WO2016207304A2 (en) 2015-06-26 2016-12-29 Mab Discovery Gmbh Monoclonal anti-il-1racp antibodies
US11198728B2 (en) 2015-06-26 2021-12-14 Sanofi Biotechnology SAS Monoclonal anti-IL-1RAcp antibodies
WO2017072210A1 (en) 2015-10-29 2017-05-04 F. Hoffmann-La Roche Ag Anti-variant fc-region antibodies and methods of use
WO2017191101A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
EP3889175A1 (en) 2016-05-02 2021-10-06 F. Hoffmann-La Roche AG The contorsbody - a single chain target binder
WO2017191325A1 (en) 2016-05-06 2017-11-09 Mab Discovery Gmbh Humanized anti-il-1r3 antibodies
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US11203642B2 (en) 2016-05-06 2021-12-21 Sanofi Biotechnology SAS Humanized anti-IL-1R3 antibodies
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
WO2017210443A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
WO2018033798A1 (en) 2016-08-17 2018-02-22 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3617232A1 (en) 2016-08-17 2020-03-04 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018071919A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
WO2018071918A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
WO2018129522A1 (en) 2017-01-09 2018-07-12 Torch Therapeutics Conditionally effective bispecific therapeutics
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US11639392B2 (en) 2017-05-08 2023-05-02 Sanofi Biotechnology Anti-IL-1R3 antibodies for use in inflammatory conditions
WO2018206565A1 (en) 2017-05-08 2018-11-15 Mab Discovery Gmbh Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
WO2018223002A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
WO2018220446A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
WO2019086394A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag The compbody - a multivalent target binder
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
WO2019157340A1 (en) 2018-02-08 2019-08-15 Amgen Inc. Low ph pharmaceutical antibody formulation
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204592A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
WO2019210147A1 (en) 2018-04-27 2019-10-31 Xencor, Inc. Dosing of a bispecific antibody that bind cd123 and cd3
WO2019232528A1 (en) 2018-06-01 2019-12-05 Xencor, Inc. Dosing of a bispecific antibody that bind cd123 and cd3
WO2019232484A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
WO2020010079A2 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
US11530274B2 (en) 2018-07-02 2022-12-20 Amgen Inc. Anti-STEAP1 antigen-binding protein
WO2020018556A1 (en) 2018-07-16 2020-01-23 Amgen Inc. Method of treating multiple myeloma
WO2020077276A2 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
WO2020154540A1 (en) 2019-01-23 2020-07-30 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
WO2021072298A1 (en) 2019-10-11 2021-04-15 Genentech, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
WO2021113831A1 (en) 2019-12-05 2021-06-10 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
WO2021155042A1 (en) 2020-01-28 2021-08-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
WO2022097065A2 (en) 2020-11-06 2022-05-12 Novartis Ag ANTIBODY Fc VARIANTS
WO2022127793A1 (en) 2020-12-18 2022-06-23 珠海泰诺麦博生物技术有限公司 Respiratory syncytial virus-specific binding molecule
WO2022140701A1 (en) 2020-12-24 2022-06-30 Xencor, Inc. Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains
WO2023010031A1 (en) 2021-07-28 2023-02-02 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023015198A1 (en) 2021-08-04 2023-02-09 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
WO2023175498A1 (en) 2022-03-17 2023-09-21 Pfizer Inc. Improved igg-degrading enzymes and methods of use thereof
WO2023196905A1 (en) 2022-04-07 2023-10-12 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains

Also Published As

Publication number Publication date
WO1998048032A3 (en) 1999-01-28
EP0915987A2 (en) 1999-05-19

Similar Documents

Publication Publication Date Title
WO1998048032A2 (en) POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
RU2004137825A (en) BACTERIA PRODUCING L-AMINO ACID AND METHOD FOR PRODUCING L-AMINO ACID
WO1992016462A1 (en) Polyaspartic acid as a calcium carbonate and a calcium phosphate inhibitor
JP2000505291A (en) Transaminase and aminotransferase
CN104178532A (en) Preparation of 6-aminocaproic acid from 5-formyl valeri C acid
US6465233B1 (en) Nucleic acid molecule encoding a cephalosporin acetylesterase
CN110777123B (en) Mutant L-amino acid ligase and process for preparing L-glutamic acid-L-tryptophan dipeptide by enzyme catalysis method
KR100901554B1 (en) Dna encoding novel enzyme having d-serine synthase activity, method of producing the enzyme and method of producing d-serine by using the same
CN112280755B (en) Mutant enzyme, application thereof and process for preparing sanshengtai by enzyme catalysis method
AU1692095A (en) Polyaspartic acid having more than 50 per cent beta form and less than 50 per cent alpha form
BR0006915A (en) Nucleotide sequences for the gene as
KR20020020898A (en) Process for producing amide compounds
KR100482686B1 (en) Method of purifying amide compound
Heider et al. Occurrence and functional compatibility within Enterobacteriaceae of a tRNA species which inserts selenocysteine into protein
Schroeder et al. Peptidase D of Escherichia coli K-12, a metallopeptidase of low substrate specificity
EP1302472A1 (en) Molecules capable of binding to telomere and the like and method with the use of the same
WO2000023609A1 (en) Transaminase biotransformation process employing glutamic acid
US5427934A (en) Genetic engineering process for the production of S-(+)-2,2-dimethylcyclopropanecarboxamide by microorganisms
Deguchif et al. Periodic Polypeptides Based on Poly (L-Alanylglycine): Biological Synthesis and Verification of the Structure of A Series of Polymers Containing Tandem—(Alagly) xGlugly—Repeats
KR100365838B1 (en) A New thermostable D-stereospecific dipeptidase from Brevibacillus borstelensis BCS-1 and its use as a biocatalyst for the synthesis of peptides containing D-amino acids
EP1306438A4 (en) Novel carbonyl reductase, gene thereof and method of using the same
US5968801A (en) Polyhydroxyalkanoate depolymerase and process for producing the same
RU2805253C1 (en) New modified polypeptide with reduced citrate synthase activity and method for producing l-amino acid using it
KR100311891B1 (en) Gene Coding for Heat-resistant Glutamate Racemase of Aquifex pyrophilus, Heat-resistant Glutamate Racemase Expressed therefrom, and Method for Preparing the Same
Asgeirsson et al. Alkaline phosphatase from a marine Vibrio sp.: Heat-lability coincides with high catalytic efficiency

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1998922651

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1998922651

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09202839

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998922651

Country of ref document: EP